Theralase Technologies Inc. (CVE:TLT – Get Free Report)’s stock price dropped 10.6% during trading on Wednesday . The company traded as low as C$0.21 and last traded at C$0.21. Approximately 122,607 shares changed hands during mid-day trading, an increase of 2% from the average daily volume of 119,964 shares. The stock had previously closed at C$0.24.
Theralase Technologies Price Performance
The firm has a market capitalization of C$53.57 million, a price-to-earnings ratio of -11.72 and a beta of 1.36. The stock’s fifty day moving average price is C$0.27 and its two-hundred day moving average price is C$0.24. The company has a current ratio of 1.91, a quick ratio of 3.40 and a debt-to-equity ratio of 14.85.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Read More
- Five stocks we like better than Theralase Technologies
- How to Invest in Insurance Companies: A Guide
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- 3 REITs to Buy and Hold for the Long Term
- Why Energy Transfer Belongs on Your Watchlist
- How to Use the MarketBeat Stock Screener
- Why Wayfair Stock May Be a Hidden Gem for Value Investors
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
